Table 1.
iStent randomized controlled trials: summary of results
| Study | Treatment group (n= number of eyes) | Control group (n= number of eyes) | Follow-up (months) | Attrition rate, treatment group/control group (%) | Treatment group mean IOP reduction (%) | Control group mean IOP change (% reduction) | Treatment group mean medications (% reduction) | Control group mean medications (% reduction) |
|---|---|---|---|---|---|---|---|---|
| Fea14 | Phaco +1 iStent (n=12) | Phaco (n=24) | 15 | 0.0/12.5 | 17.3* | 9.2 | 80* | 31.6 |
| Fernández-Barrientos et al15 | Phaco +2 iStents (n=17) | Phaco (n=16) | 12 | 0.0/0.0 | 27.3** | 16.5 | 100* | 41.7 |
| Samuelson et al10 | Phaco +1 iStent (n=117) | Phaco (n=123) | 12 | 9.4/8.9 | 8.2 | 5.4 | 86.7* | 73.3 |
| Craven et al13 | Phaco +1 iStent (n=117) | Phaco (n=123) | 24 | 16.2/17.9 | 8.1 | 4.3 | 80.0 | 66.7 |
Notes: The values listed under the columns “mean IOP change” and “mean medications” indicate the reduction from baseline. P-values where available from original publication:
*
P<0.05,
**
P<0.005.
Abbreviations: IOP, intraocular pressure; phaco, phacoemulsification.